share_log

德琪醫藥-B：截至2023年12月31日止年度年度業績公告及建議修訂現有組織章程大綱及章程細則並採納新組織章程大綱及章程細則及更改所得款項用途

ANTENGENE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION AND CHANGE IN USE OF PROCEEDS

香港交易所 ·  Mar 22 04:41
Summary by Moomoo AI
德琪醫藥有限公司公佈截至2023年12月31日止年度的業績，報告期內收入較去年同期下降，主要由於中國大陸收入減少，包括自願下調希維奧®（塞利尼索）價格、一次性負面調整銷售額以及與翰森製藥的商業化合作。研發成本及銷售及分銷開支均有所下降，反映公司降本增效策略。年內虧損較去年減少，並提出修訂現有組織章程大綱及章程細則。公司未來將重點投資於具有全球權利的資產，並無派發股息。股東週年大會將於2024年6月14日舉行。
德琪醫藥有限公司公佈截至2023年12月31日止年度的業績，報告期內收入較去年同期下降，主要由於中國大陸收入減少，包括自願下調希維奧®（塞利尼索）價格、一次性負面調整銷售額以及與翰森製藥的商業化合作。研發成本及銷售及分銷開支均有所下降，反映公司降本增效策略。年內虧損較去年減少，並提出修訂現有組織章程大綱及章程細則。公司未來將重點投資於具有全球權利的資產，並無派發股息。股東週年大會將於2024年6月14日舉行。
DEKI PHARMACEUTICALS CO., LTD. ANNOUNCED RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023. REVENUE FOR THE REPORTING PERIOD DECREASED COMPARED TO THE SAME PERIOD LAST YEAR, MAINLY DUE TO LOWER REVENUES IN MAINLAND CHINA, INCLUDING VOLUNTARY REDUCTIONS IN SIVIO® (SELENISO) PRICES, ONE-TIME NEGATIVE SALES ADJUSTMENTS, AND COMMERCIALIZATION COOPERATION WITH JOHNSON PHARMACEUTICALS. R&D costs and sales and distribution expenses decreased, reflecting the Company's strategy of reducing capital efficiency. The loss for the year was reduced compared to the previous year and amendments were made to the existing articles of association and the rules of association. In the future, the company will invest heavily in assets with global rights and will not distribute dividends. The Annual General Meeting will be held on 14 June 2024.
DEKI PHARMACEUTICALS CO., LTD. ANNOUNCED RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023. REVENUE FOR THE REPORTING PERIOD DECREASED COMPARED TO THE SAME PERIOD LAST YEAR, MAINLY DUE TO LOWER REVENUES IN MAINLAND CHINA, INCLUDING VOLUNTARY REDUCTIONS IN SIVIO® (SELENISO) PRICES, ONE-TIME NEGATIVE SALES ADJUSTMENTS, AND COMMERCIALIZATION COOPERATION WITH JOHNSON PHARMACEUTICALS. R&D costs and sales and distribution expenses decreased, reflecting the Company's strategy of reducing capital efficiency. The loss for the year was reduced compared to the previous year and amendments were made to the existing articles of association and the rules of association. In the future, the company will invest heavily in assets with global rights and will not distribute dividends. The Annual General Meeting will be held on 14 June 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more